OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine

Expert Opinion on Biological Therapy

Volumn 10, Issue 2, 2010, Pages 289-298

  Cady, Roger K ^a  

^a HEADACHE CARE CENTER   (United States)

Author keywords

Botulinum toxin type A; Chronic migraine; Migraine; Onabotulinumtoxina; Preventive therapy; Prophylactic therapy

Indexed keywords

BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; GABAPENTIN; NEUROPEPTIDE; PLACEBO; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TOPIRAMATE; VALPROATE SEMISODIUM;

CHRONIC DAILY HEADACHE; CLINICAL PRACTICE; CLINICAL TRIAL; DIPLOPIA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; EPISODIC MEMORY; EPISODIC MIGRAINE; EXOCYTOSIS; EXPLODING HEADACHE; EYELID EDEMA; HEADACHE; HEADACHE AND FACIAL PAIN; HUMAN; IMPLODING HEADACHE; LOCAL SITE PARESTHESIA; MIGRAINE; MUSCLE WEAKNESS; NECK PAIN; NOCICEPTION; OCULAR HEADACHE; PARALYSIS; PARENTERAL NUTRITION; PARESTHESIA; PTOSIS; REVIEW; SPASTICITY; STIFF NECK; STRABISMUS; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BOTULINUM TOXIN TYPE A; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS;

EID: 76149116558     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903586221     Document Type: Review

References (51)

1. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-973
2. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349
3. Mathew NT, Stubits E, Nigam MR. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982;22:66-68
4. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache 1987;27:102-106
5. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96
6. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45(Suppl 1):S3-13
7. Kurth T, Schürks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology 2009;73(8):581-588
8. Palm-Meinders IH, Koppen H, Terwindt GM, et al. Progression of brain white matter lesions in migraine? The 9-year follow-up population-based CAMERA-2 study. [Abstract LBOR5]. Cephalalgia 2009;49:1351
9. Kruit M, Launer LJ, Ferrari M, van Buchemm MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 2005;128:2066-2077
10. Cady RK, Mathew N, Diener H-C, et al. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009;49:216-226
11. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:109-112
12. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669-676
13. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349
14. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41(7):646-657
15. Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie IK, editor, Epidemiology of pain. IASP Press, Seattle, WA; 1999. p. 159-170
16. Cady RK. The epidemiology and pathophysiology of migraine. Manag Care 2007;16(7 Suppl 7):4-9
17. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-645 (Pubitemid 32777746)
18. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study. Headache 2007;47:355-363
19. Silberstein S, Diener HC, Lipton R, et al. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache 2008;48:1087-1095
20. Felber ES. Botulinum toxin in primary care medicine. J Am Osteopath Assoc 2006;106:609-614
21. Simpson DM, Gracies J-M, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698
22. Bakheit AM, Fedorova NV, Skoromets AA, et al. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004;75:1558-1561
23. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44(1):35-42
24. Durham PL. CGRP-receptor antagonists- a fresh approach to migraine therapy? N Engl J Med 2004;350:1073-1075
25. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43(Suppl 1):S16-24
26. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(Suppl 1):S9-S15
27. Aoki KR. Basic aspects of botulinum toxin: physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol 2002;30:107-116
28. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365(6442):160-163
29. Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol 2000;15(Suppl 3):28-35
30. Caleo M, Antonucci F, Restani L, Mazzocchio R. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem 2009;109(1):15-24
31. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-450
32. Farinelli I, Coloprisco G, DeFillippis S, Martelletti P. Long-term benefits of botulinum toxin type A (Botox) in chronic daily headache: a five-year long experience. J Headache Pain 2006;7:407-412
33. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47:486-499
34. Mathew NT, Jaffri SFA. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009;49:1466-1478
35. Freitag FG, Diamond S, Diamond M, et al. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008;48:201-209
36. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008;48:210-220
37. Jakubowski M, McAllister PJ, Bajwa ZH, et al. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 2006;125(3):286-295
38. Cady RK, Schreiber CP. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 2008;48:900-913
39. Dodick DW, Aurora SK, Turkel CC, et al. Botulinum toxin type A for treatment of chronic migraine: the double blind phase of the PREEMPT clinical program [abstract# P057]. Cephalalgia 2009;29(Suppl 1):34
40. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17(2):103-108
41. Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006;46(4):642-648
42. US Food and Drug Administration. Available from: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/Drug SafetyInformationforHealthcare Professionals/ucm174949.htm
43. Cady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide (CGRP) levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009;49(9):1258-1266
44. Relja M, Poole AC, Schoenen J, et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007;27(6):492-503
45. Shuhendler AJ, Lee S, Siu M, et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo controlled trials. Pharmacotherapy 2009;29:784-791
46. Saper JR, Mathew NT, Loder EW, et al. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007;8(6):478-485
47. Elkind AH, O'Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006;7:688-696
48. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine: a randomized, doubleblind, placebo-controlled study. Cephalalgia 2004;24:838-843
49. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebocontrolled, parallel design study. Cephalalgia 2004;24:60-65
50. Dodick DW, Mauskop A, Elkind AH, et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis\ of patients not receiving other prophylactic medications:a randomized double-blind, placebo-controlled study. Headache 2005;45:315-324
51. Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293-307